Synthetic Biology Market By Products(Synthetic DNA, Synthetic genes, Software tools, Synthetic cells, Chassis …Medgadget (blog)Pharmaceutical and diagnostic application segment would continue to dominate throughout the forecast period. This is attrib… Continue reading
News-Medical.netStudy suggests how existing and emerging immunotherapy treatments could be successful for sarcomasNews-Medical.netSarcomas – cancers of the connective tissues like muscles, joints, fat and bone -; come in dozens of subtypes. Clinical tr… Continue reading
Nature.comCancer Immunotherapy: T cells tackle tumoursNature.comUsing targeted T cell therapies to treat cancer has the potential to be a more precise arsenal against the disease compared with chemotherapy and radiotherapy. However, conventional method… Continue reading
Financial Express Bangladesh |
Expensive gene therapy gets its second patient
Financial Express Bangladesh Gene therapy had a rocky start. Last month a Biotech company UniQure said it would pull its gene therapy Glybera from the market in Europe after treating only one patient because lack of demand. Its drug costs $1.0 million, the world’s most expensive … |
Financial Express Bangladesh |
Expensive gene therapy gets its second patient
Financial Express Bangladesh Gene therapy had a rocky start. Last month a Biotech company UniQure said it would pull its gene therapy Glybera from the market in Europe after treating only one patient because lack of demand. Its drug costs $1.0 million, the world’s most expensive … |
|
Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference
Nasdaq The Company utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T–Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR … |